Gritstone bio, Inc.
Built from real-time financials and updated daily. For a full Analyst Grade with bull/bear case, price targets, and qualitative risk analysis, generate a GRTS research report →
Companygritstonebio.com
Gritstone bio, Inc. , a clinical-stage biotechnology company, engages in developing immunotherapies against multiple cancer types and infectious diseases. Its lead product candidate is GRANITE, a neoantigen-based immunotherapy for the treatment of solid tumors, including metastatic non-small cell lung cancer, as well as gastroesophageal, bladder and microsatellite stable, and colorectal cancers.
- CEO
- Andrew R. Allen BCh, BM, MA, MRCP,
- IPO
- 2018
- Employees
- 231
- HQ
- EmeryVille, CA, US
Price Chart
Valuation
- Market Cap
- $3.80M
- P/E
- -0.03
- P/S
- 2.86
- P/B
- 0.07
- EV/EBITDA
- -0.34
- Div Yield
- 0.00%
Profitability
- Gross Margin
- -470.32%
- Op Margin
- -11617.88%
- Net Margin
- -10404.96%
- ROE
- -124.41%
- ROIC
- -94.15%
Growth & Income
- Revenue
- $1.33M · -85.64%
- Net Income
- $-138,490,000 · -22.42%
- EPS
- $-1.20 · 3.23%
- Op Income
- $-154,634,000
- FCF YoY
- -3.61%
Performance & Tape
- 52W High
- $3.17
- 52W Low
- $0.03
- 50D MA
- $0.40
- 200D MA
- $1.17
- Beta
- 0.50
- Avg Volume
- 17.01M
Get TickerSpark's AI analysis on GRTS
Pro members can request AI-generated analysis on any ticker — technical setup, analyst consensus, earnings watch, insider pulse, financial health, and peer context. Ready in about a minute.
Get Pro Access →30-day money-back guarantee · cancel anytime
Recent Insider Transactions
| Date | Insider | Type | Shares |
|---|---|---|---|
| Apr 4, 25 | Rizvi Naiyer | other | 7,500 |
| Apr 4, 25 | Rizvi Naiyer | other | 19,000 |
| Apr 4, 25 | Rizvi Naiyer | other | 38,000 |
| Apr 4, 25 | Rizvi Naiyer | other | 937 |
| Apr 4, 25 | Rizvi Naiyer | other | 10,000 |
| Apr 4, 25 | Rizvi Naiyer | other | 4,347 |
| Apr 4, 25 | Rizvi Naiyer | other | 51,800 |
| Apr 4, 25 | Economides Vassiliki | other | 138,000 |
| Apr 4, 25 | Economides Vassiliki | other | 215,000 |
| Apr 4, 25 | Economides Vassiliki | other | 215,000 |
Our GRTS Coverage
We haven't published any research on GRTS yet
For a full analyst-grade research report — grades, price targets, full financials, chart analysis — generate one on demand.
Generate GRTS Report →